Minimally invasive options expand for uterine fibroids

March 9, 2019

Acessa Health Inc., developer of the Acessa System and the staff of Dedicated Women ObGyn in Dover announced they were the first in Delaware to complete the Acessa Procedure for uterine fibroids, using the latest Acessa ProVu technology. Acessa Health Inc. also announced the medical policy decision by Highmark Inc. to cover the procedure.

Also known as laparoscopic radiofrequency ablation for fibroids, the Acessa Procedure is a minimally invasive method for treating uterine fibroids. Studies have shown more than 70 percent of women have uterine fibroids, which can cause abnormal heavy menstruation, pelvic pain and bulk symptoms.

Hysterectomy prevails as the primary surgical treatment in the United States, even though studies show women increasingly desire less-invasive options. The Acessa Procedure revolutionizes the standard of care for fibroids. The procedure treats almost all sizes and locations of fibroids, including those outside the uterine cavity and within uterine walls. The procedure requires no cutting or suturing of uterine tissue, and patients typically go home the same day, experiencing minimal discomfort and a rapid return to normal activities.

With 17 providers, Dedicated to Women ObGyn is nationally recognized for its collaborative care approach. Dr. Laura Moylan and Dr. Robert Hartmann are the two physicians offering the Acessa Procedure for patients with surgeries being performed locally at the Delaware Surgery Center. Moylan and Hartmann each recently completed Acessa procedures marking the first in Delaware. Both patients had successful outcomes and are already seeing positive symptom relief.

“We are excited to bring this offering to women in the Delaware region,” said Moylan,  a board-certified OBGYN. “The Acessa System allows us to treat nearly all fibroids in nearly all locations. Before, when a patient came to us with symptomatic fibroids, I could offer her a myomectomy or hysterectomy, or I could refer them to a radiologist for uterine artery embolization. As a clinician, I would prefer to offer a less-invasive option as a first-line surgical treatment. Now, with the Acessa Procedure, I can offer them an outpatient, same-day procedure that is proven to solve their fibroid symptoms. It is a game changer.”

“The technology is outstanding and aligns with our mission,” said Hartmann, who has served patients in Dover for more than 20 years. The Acessa ProVu system integrates radiofrequency ablation, laparoscopic ultrasound and guidance mapping. “Dedicated to Women’s mission is to provide exceptional, progressive women’s healthcare in a compassionate environment. With the Acessa Procedure, we are compounding our ability to provide exceptional care for women with fibroids.”

To schedule a consultation to be evaluated for fibroids and whether the Acessa Procedure is an appropriate treatment option, contact Dedicated to Women ObGyn at 302-674-0223.

Highmark Inc. now covers the procedure. Highmark’s Medical Policy team conducted a third-party independent review of the technology, outcomes and clinical studies which resulted in overwhelming evidence that the Acessa system is safe, effective and proven. This decision comes at a pivotal moment when women across the nation are seeking minimally invasive alternatives to hysterectomy. 


Subscribe to the Daily Newsletter